These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17638621)

  • 1. The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.
    Kuo WH; Chang LY; Liu DL; Hwa HL; Lin JJ; Lee PH; Chen CN; Lien HC; Yuan RH; Shun CT; Chang KJ; Hsieh FJ
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):135-45. PubMed ID: 17638621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.
    Filardo EJ; Graeber CT; Quinn JA; Resnick MB; Giri D; DeLellis RA; Steinhoff MM; Sabo E
    Clin Cancer Res; 2006 Nov; 12(21):6359-66. PubMed ID: 17085646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
    Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.
    Zhao H; Chen D; Wang J; Yin Y; Gao Q; Zhang Y
    Int J Clin Exp Pathol; 2014; 7(2):670-6. PubMed ID: 24551288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
    Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
    Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
    Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases].
    Guan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):196-9. PubMed ID: 18756935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
    Kunju LP; Ding Y; Kleer CG
    Pathol Int; 2008 Oct; 58(10):620-5. PubMed ID: 18801081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity?
    Kiani J; Khan A; Khawar H; Shuaib F; Pervez S
    Pathol Oncol Res; 2006; 12(4):223-7. PubMed ID: 17189985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
    Girgert R; Emons G; Gründker C
    Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of E-cadherin and c-erbB-2/HER-2/neu oncoprotein in high-grade breast cancer.
    Turashvili G; Bouchalova K; Bouchal J; Kolar Z
    Cesk Patol; 2007 Jul; 43(3):87-92. PubMed ID: 17821836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.